Recrutamento encerrado
FASE
Número Europeu 2014-004944-37
MK3475-054
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group
Detalhes
Destaques